-
摘要: 抗血小板药物在各种动脉血栓性疾病防治中具有重要地位。虽然目前抗血小板药物多采用固定剂量给药,但不同患者对抗血小板治疗的反应性存在明显差异。治疗后的血小板高反应性或低反应性可能与血栓事件或出血事件风险相关。基于血小板功能检测的个体化抗血小板治疗方案可能有助于预防血栓或出血不良事件的发生,但目前仍缺乏上述治疗策略能够最终改善患者预后的确切临床证据。迄今为止,对于接受抗血小板治疗的患者是否应常规进行实验室监测仍存在诸多争议。本文对抗血小板治疗反应多样性的成因及血小板功能检测是否可用于指导个体化抗血小板治疗进行讨论。Abstract: Antiplatelet therapy is of proven benefit to arterial thrombotic diseases. Although antiplatelet agents are usually given on fixed dosages, there is great interindividual variability in pharmacodynamic response to antiplatelet medications. Patients with high on-treatment platelet reactivity are at increased risk for thrombotic events. On the contrary, low on-treatment platelet reactivity has been linked to a higher risk of bleeding. Personalized antiplatelet treatment strategies based on platelet function monitoring constitute a promising tool for the prevention of both thrombotic and bleeding events, but the conclusive evidence for improved clinical outcomes with such approaches is yet lacking. Up to now, whether routine laboratory monitoring of antiplatelet therapy is of clinical benefit is still controversial. This review discusses the causes of variability in the response to aspirin or clopidogrel and highlights the current position of platelet function testing in guiding personalized antiplatelet therapy.
-
Key words:
- aspirin /
- clopidogrel /
- platelet function, testing
-
[1] Orme R, Judge HM, Storey RF. Monitoring antiplatelet therapy [J]. Semin Thromb Hemost, 2017, 43: 311-319. doi: 10.1055/s-0036-1597298 [2] Michelson AD, Bhatt DL. How I use laboratory monitoring of antiplatelet therapy?[J]. Blood, 2017, 130: 713-721. doi: 10.1182/blood-2017-03-742338 [3] Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease [J]. J Am Coll Cardiol, 2007, 50: 1822-1834. doi: 10.1016/j.jacc.2007.07.051 [4] Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adeno-sine diphosphate associated with ischemia and bleeding [J]. J Am Coll Cardiol, 2013, 62: 2261-2273. doi: 10.1016/j.jacc.2013.07.101 [5] Jovanovic L, Antonijevic N, Novakovic T, et al. Practical aspects of monitoring of antiplatelet therapy [J]. Semin Thromb Hemost, 2017, 43: 14-23. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=f94cca36d07f692d877ca43f77dcb8e1 [6] Patrono C. The multifaceted clinical readouts of platelet inhibition by low-dose aspirin [J]. J Am Coll Cardiol, 2015, 66:74-85. doi: 10.1016/j.jacc.2015.05.012 [7] Price MJ, Berger PB, Teirstein PS, et al.Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial [J]. JAMA, 2011, 305: 1097-1105. doi: 10.1001/jama.2011.290 [8] Collet JP, Cuisset T, Rang'e G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting [J]. N Engl J Med, 2012, 367: 2100-2109. doi: 10.1056/NEJMoa1209979 [9] Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial [J]. Lancet, 2016, 388: 2015-2022. doi: 10.1016/S0140-6736(16)31323-X [10] Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) [J]. Eur Heart J, 2014, 35: 2541-2619. doi: 10.1093/eurheartj/ehu278 [11] Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions [J]. J Am Coll Cardiol, 2011, 58: e44-e122. http://www.researchgate.net/publication/281297740_ACCFAHASCAI_guideline_for_percutaneous_coronary_intervention_executive_summary_a_report_of_the_American_College_of_Cardiology_FoundationAmerican_Heart_Association_Task_Force_on_Practice_Guidelines_and [12] Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) [J]. Eur Heart J, 2017. doi: 10.1093/eurheartj/ehx419. [Epub ahead of print]. [13] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会.抗血小板药物治疗反应多样性临床检测和处理的中国专家建议[J].中华心血管病杂志, 2014, 42: 986-991. doi: 10.3760/cma.j.issn.0253-3758.2014.12.002
点击查看大图
计量
- 文章访问数: 243
- HTML全文浏览量: 37
- PDF下载量: 134
- 被引次数: 0